IMC gp100

Drug Profile

IMC gp100

Alternative Names: IMCgp100; ImmTAC-gp100; Monoclonal T cell receptor anti-CD3 scFv fusion protein (IMCgp100)

Latest Information Update: 11 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunocore
  • Developer Immunocore; MedImmune
  • Class Cancer vaccines; Proteins
  • Mechanism of Action CD3 antigen inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveal melanoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malignant melanoma; Uveal melanoma

Most Recent Events

  • 05 Sep 2018 Immunocore has patent protection for ImmTAC platform in Europe and China
  • 05 Sep 2018 Immunocore receives patent allowance for ImmTAC platform in USA
  • 04 Jun 2018 Interim adverse events and efficacy data from a phase I trial in Uveal melanoma released by Immunocore
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top